Search the P2X7 related biomarkers for Alzheimer’s disease
Alzheimer’s disease is an age-related dementia with major impact in people aged 60 or over.
Typical symptoms including memory loss and cognitive impairment but the pathogenesis is unclear and treatment options are limited. Recent evidence suggests the P2X7 receptor may be involved in the pathogenesis of this disease. This project will study the peripheral blood cells obtained from Alzheimer’s disease patients, subjects with minor cognitive impairment and age matched healthy controls. The P2X7 expression and function on mononuclear cells and various phenotyping and serological assays will be performed. The diagnostic and prognostic values of P2X7 expression and function will be evaluated. This work may provide a useful biomarker for the diagnosis and prognosis of Alzheimer’s disease, as well as the possible pathogenesis mechanism.
Latest Florey news for Alzheimer’s disease
A sleeping pill to slow Alzheimer’s and addiction?
What does sleep have to do with Alzheimer’s disease, and addiction?
What causes Alzheimer’s disease?
Following the recent breakthrough of a blood test to identify Alzheimer's disease, two specialists - Dr Scott Ayton and Dr Yen Ying Lim - go toe to toe to convince you their theory will cure dementia.
Major new Alzheimer’s disease initiative announced
Federal minister for Aged Care and Indigenous Health has today announced a major new initiative in Alzheimer's diagnosis, clinical trial enrolment and patient care. The Florey's Melbourne Dementia Research Centre will manage $18 million.
Minimally invasive blood test for Alzheimer’s disease announced
Scientists from Japan and Australia have teamed up to develop and validate a blood test for Alzheimer’s disease, with the potential to massively ramp up the pace of Alzheimer’s disease drug trials.
Brain health affects all Australians. You can support our research by making a donation or a bequest.